FN2 Earnings Intelligence
United Therapeutics Corporation income statement
United Therapeutics Corporation (UTHR) Income Statement (annual) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - |
| - Cash | $894.8 | $961.2 | $1,207.7 | $1,697.2 | $1,557.1 |
| + Debt | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - |
| Revenue | $1,685.5 | $1,936.3 | $2,327.5 | $2,877.4 | $3,182.7 |
| % Growth | 13.6% | 14.9% | 20.2% | 23.6% | 10.6% |
| Gross Profit | $1,563 | $1,784.7 | $2,070 | $2,567.7 | $2,798.3 |
| % Margin | 92.7% | 92.2% | 88.9% | 89.2% | 87.9% |
| EBITDA | $605.8 | $1,031 | $1,238.1 | $1,449.5 | $1,578.1 |
| % Margin | 35.9% | 53.2% | 53.2% | 50.4% | 49.6% |
| Net Income | $475.8 | $727.3 | $984.8 | $1,195.1 | $1,334.7 |
| % Margin | 28.2% | 37.6% | 42.3% | 41.5% | 41.9% |
| Diluted EPS | $10.06 | $15.00 | $19.81 | $24.64 | $27.86 |
| % Growth | -12.8% | 49.1% | 32.1% | 24.4% | 13.1% |
| Operating Cash Flow | $598.2 | $802.5 | $978 | $1,327.1 | $1,561.2 |
| CapEx | $120.8 | $138.8 | $230.4 | $246.5 | $520.5 |
| Free Cash Flow | $477.4 | $663.7 | $747.6 | $1,080.6 | $1,040.7 |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue | $1,685.5 | $1,936.3 | $2,327.5 | $2,877.4 | $3,182.7 |
| Gross Profit | $1,563 | $1,784.7 | $2,070 | $2,567.7 | $2,798.3 |
| EBITDA | $605.8 | $1,031 | $1,238.1 | $1,449.5 | $1,578.1 |
| Net Income | $475.8 | $727.3 | $984.8 | $1,195.1 | $1,334.7 |
| Diluted EPS | $10.06 | $15.00 | $19.81 | $24.64 | $27.86 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $894.8 | $961.2 | $1,207.7 | $1,697.2 | $1,557.1 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $598.2 | $802.5 | $978 | $1,327.1 | $1,561.2 |
| Capital Expenditure | $120.8 | $138.8 | $230.4 | $246.5 | $520.5 |
| Free Cash Flow | $477.4 | $663.7 | $747.6 | $1,080.6 | $1,040.7 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 13.6% | 14.9% | 20.2% | 23.6% | 10.6% |
| Gross Margin | 92.7% | 92.2% | 88.9% | 89.2% | 87.9% |
| EBITDA Margin | 35.9% | 53.2% | 53.2% | 50.4% | 49.6% |
| Net Margin | 28.2% | 37.6% | 42.3% | 41.5% | 41.9% |
| FCF Margin | 28.3% | 34.3% | 32.1% | 37.6% | 32.7% |
| Diluted EPS Growth | -12.8% | 49.1% | 32.1% | 24.4% | 13.1% |
Get the UTHR recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.